Form 4 for GILD Gilead Sciences
Accepted 2026-08-18 18:54:04 ET · period of report 2026-08-17 · accession 0001782135-26-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-18 18:54 | 2026-08-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $67.07 | +25.0K | 146.2K | +21% | +$1.68M |
| DMT | 2026-08-18 18:54 | 2026-08-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | S - Sale+OE | $137.64 | -28.0K | 118.2K | -19% | -$3.85M |
| DMT | 2026-08-18 18:54 | 2026-08-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $0.00 | -25.0K | 70.0K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | M | A | 23,110 | $66.64 | 144,344 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. |
| 2 | Common | Common Stock | 2026-08-17 | M | A | 1,890 | $72.34 | 146,234 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. |
| 3 | Common | Common Stock | 2026-08-17 | S | D | 16,530 | $137.37 | 129,704 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F2) Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 4 | Common | Common Stock | 2026-08-17 | S | D | 11,470 | $138.04 | 118,234 | D | — | — | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F3) Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-08-17 | M | D | 23,110 | $0.00 | 0 | D | $66.64 · — to 2029-07-24 | 23,110 Common Stock | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F4) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-08-17 | M | D | 1,890 | $0.00 | 69,960 | D | $72.34 · — to 2030-03-10 | 1,890 Common Stock | (F1) The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. (F4) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |